Develops non-viral gene therapy solutions for gastrointestinal and liver diseases, utilizing its proprietary gene delivery platform.
enGene Holdings Inc., operating through its subsidiary enGene, Inc., is a clinical-stage biotechnology firm specializing in the development of genetic medicines delivered to mucosal tissues and various organs.
Leading its portfolio is EG-70 (detalimogene voraplasmid), a non-viral immunotherapy designed specifically for patients with non-muscle invasive bladder cancer and carcinoma-in-situ (Cis) who have not responded to Bacillus Calmette-Guerin treatment.
Established in 2023 and headquartered in Saint-Laurent, Canada, enGene Holdings Inc. is committed to pioneering advancements in genetic medicine delivery. The company's innovative approach holds promise for addressing critical medical needs and advancing treatment options in oncology and beyond.